"/> "/>


Reset filters
Search entire website

SIP 2017 - Presentation & Statement

Gabriel Baertschi – Grünenthal Group, Germany

SIP 2017 - Presentation & Statement
Note: As soon as you start a YouTube video on our website, a connection to the YouTube servers is established. You can find detailed information in our privacy policy.

"We see it as our commitment together with academia, patient representatives and policy makers to develop new life changing innovations bringing benefit to patients in areas with a high unmet medical need."

Gabriel Baertschi
Chief Executive Officer
Grünenthal Group

Grünenthal, a science-driven pharmaceutical company with a strong commitment to innovations in pain indications. By investing in research and development we demonstrate our commitment to innovation in order to treat unmet medical needs and deliver value-adding products to patients.

At Grünenthal we consider it our responsibility to work on innovative solutions in pain treatment. Our scientists have defined a pain landscape containing over 100 different pain conditions. Many of these indications are yet to be fully understood and often lack a proper medical treatment. We are convinced that the complex nature of pain calls for a holistic effort from prevention, through early diagnosis, to most effective treatment. This effort has to involve the patient from the beginning and has to embrace the multidisciplinary aspects of chronic pain management. In practice this means that policy makers, healthcare professionals, budget holders, and industry need to work together in order to modernize the entire approach.

About Gabriel Baertschi

In October 2016, Gabriel Baertschi took over the position as the Global CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

From 1999 until 2016 he worked with AstraZeneca in different positions and regions, as a company president for Germany, Thailand and lastly from 2013-2016 for Japan leading Commercial, R&D & Manufacturing functions. Before, he was working from 1996-1999 with Servier in Switzerland in the sales area.

From 1993-1997 he studied at the University of Neuchâtel, Switzerland and made his Master Thesis in Molecular Biology Research.

  • Register for the SIP Newsletter

    Stay informed about the most important events and news about the Societal Impact of Pain platform.

    subscribe now

  1. Societal Impact of Pain (SIP)
  2. Resources
  3. Resources Details


Essential cookies are essential for the operation of the website and can therefore not be deactivated.

Cookie information


Statistics cookies allow the collection of anonymous information about how you use our website. They help us to improve your user experience and our content.

Cookie information

External media

External media cookies allow media content to be loaded from external sources. They can also be activated when you visit the website if you encounter blocked media content.

Cookie information